{"filing":{"accession_number":"0001493152-26-032387","cik":"0001716166","ticker":"VVOS","company_name":"Vivos Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226032387/form8-k.htm"},"events":[{"id":16539,"run_id":14775,"accession_number":"0001493152-26-032387","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses a private placement (PIPE) of 3,608,496 units at $0.582 per unit, raising approximately $2.1 million in gross proceeds. Each unit comprises Series A Convertible Preferred Stock (convertible 1:1 to common stock), warrants to purchase common stock equal to 100% of conversion shares, and subscription rights. The transaction is explicitly exempt from registration under Section 4(a)(2) and Regulation D Rule 506(b), and Item 3.02 confirms unregistered sales of equity securities. This is a classic dilutive private placement raising capital through convertible securities and warrants.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":14675,"accession_number":"0001493152-26-032387","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a private placement (PIPE) of 3,608,496 units at $0.582 per unit, raising approximately $2.1 million in gross proceeds. Each unit comprises Series A Convertible Preferred Stock (convertible 1:1 to common stock), warrants to purchase common stock equal to 100% of conversion shares, and subscription rights. The transaction is explicitly exempt from registration under Section 4(a)(2) and Regulation D Rule 506(b), and Item 3.02 confirms unregistered sales of equity securities. This is a classic dilutive private placement raising capital through convertible securities and warrants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:30:36.890298+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-07-07"}]}